Document is current
Any future updates will be listed below
-
Authors
Tivadar, Simona
Hugo, Jan https://orcid.org/0000-0003-4840-2642
Fuzesiová, Kristína
Doležal, Tomáš
Turková, Barbora
Gkalpakiotis, Spyridon https://orcid.org/0000-0002-6956-5961
-
Funding
Funding for this research was provided by:
Univerzita Karlova v Praze (Cooperatio 34)
Univerzita Karlova v Praze (Internal Disciplines)
- License Information
-
More Information
Article History
Received: 5 January 2025
Accepted: 24 February 2025
First Online: 3 March 2025
Declarations
:
: Simona Tivadar has served as investigator for Novartis. Jan Hugo has served as consultant and speaker for AbbVie, Amgen, Eli Lilly, Janssen Cilaq, LEO Pharma, Novartis, Pfizer, and UCB. Kristina Fuzesiova has served as a speaker for AbbVie, Eli Lilly and UCB. Tomáš Doležal has served as a speaker and consultant for AbbVie, Amgen, Eli Lilly, Janssen Cilaq, LEO Pharma, Novartis, Pfizer, and UCB. Barbora Turkova has nothing to declare. Spyridon Gkalpakiotis has served as consultants, speakers, or investigators for AbbVie, Amgen, Eli Lilly, Janssen Cilaq, LEO Pharma, Novartis, Pfizer, and UCB.
: The study was conducted in accordance with the Helsinki Declaration of 1964 and all subsequent amendments, and all patients provided informed consent. The study was approved by the ethical committee of the University Hospital Kralovske Vinohrady under the number EK-VP /08/00/2024.
